Text Size

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier:
NCT00673751
First received: May 5, 2008
Last updated: May 6, 2008
Last verified: May 2008
History of Changes
  Purpose

The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome


Condition Intervention
Short Bowel Syndrome
 Drug: GLP-2
Drug: Placebo

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Resource links provided by NLM:

Drug Information available for: Glucagon
U.S. FDA Resources

Further study details as provided by Glostrup University Hospital, Copenhagen:

Estimated Enrollment: 8
Arms Assigned Interventions
Placebo Comparator: 2
subcutaneous isotonic saline
 Drug: Placebo
Active Comparator: 1
subcutaneous GLP-2
 Drug: GLP-2
450 nmol subcutaneous

Detailed Description:

previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnose of short bowel syndrome 4 month of stable fase

Exclusion Criteria:

  • activity in IBD
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00673751

Locations
Denmark
Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
  More Information

No publications provided

Responsible Party: Lasse Bremholm, Dept. of gastroenterology, Glostrup Hospital, University of Copenhagen
ClinicalTrials.gov Identifier: NCT00673751     History of Changes
Other Study ID Numbers: H-A-2008-032
Study First Received: May 5, 2008
Last Updated: May 6, 2008
Health Authority: Denmark: National Board of Health

Keywords provided by Glostrup University Hospital, Copenhagen:
mesenteric blood flow
GLP-2
short bowel syndrome
Glucagon-Like Peptide 2

Additional relevant MeSH terms:
Short Bowel Syndrome
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
 Digestive System Diseases
Postoperative Complications
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013